跳至主要内容
临床试验/NCT05421195
NCT05421195Unknown不适用

Clinical Treatment Research of COVID-19-related Olfactory Dysfunction: A Randomized Controlled Trial

Eye & ENT Hospital of Fudan University1 个研究点 分布在 1 个国家目标入组 124 人开始时间: 2022年6月17日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
入组人数
124
试验地点
1
主要终点
Olfactory function test result:the sum of the scores of odor threshold (T), odor discrimination (D), and odor identification (I) is TDI.

研究概览

简要总结

Studies have demonstrated that patients with COVID-19- related olfactory dysfunction could improve the olfactory function after olfactory training. But the efficacy of oral corticosteroids is controversial. Some evidences shown that corticosteroid treatment would benefit post-COVID-19 olfactory dysfunction and the purpose of this study is to evaluate its efficacy.

详细描述

Reports of COVID-19-related olfactory dysfunction describe a sudden onset of olfactory impairment, which may be in the presence or absence of other symptoms. The possibility that olfactory dysfunction could act as a marker for disease. When COVID-19-related olfactory dysfunction improves spontaneously, specific treatment may not be required. However,when impairment persists beyond 2 weeks, it may be reasonable for treatment to be considered. The efficacy of available treatments for patients with COVID-19-related olfactory dysfunction is unknown. Olfactory training involves repeat and deliberate sniffing of a set of odorants (commonly lemon, rose, cloves, and eucalyptus) for 20 seconds each at least twice a day for at least 3 months (or longer if possible). Studies have demonstrated improved olfaction in patients after olfactory training. Olfactory training can be considered for patients with persistent COVID-19-related olfactory dysfunction. Some evidences shown that corticosteroid treatment would benefit post-COVID-19 olfactory dysfunction but the evidences is not adequate. Until now, the efficacy of oral corticosteroids is controversial. This study investigate the efficacy and the safety of oral corticosteroids and olfactory training as a treatment for patients with COVID-19-related olfactory dysfunction.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Previous diagnosis of COVID-19 infection;
  • Olfactory function was normal in the past, and the olfactory function decreased due to COVID-19 infection, which has occurred more than 2 weeks;
  • Olfactory function test score: TDI ≤ 30; 4.18 ≤ age ≤ 55 years old; 5.Good overall physical condition, without other diseases that may affect the test;
  • No active infection, such as uncontrolled pneumonia;
  • Women with reproductive potential and sexually active men agree to use acceptable and effective contraceptive methods.

排除标准

  • Participants who refuse to sign informed consent;
  • Participants who have other diseases that affect the result, such as trauma, benign and malignant tumors of nasal cavity and paranasal sinuses, intracranial benign and malignant tumors, etc;
  • Participants with uncontrolled concurrent diseases that the researcher believes will interfere with the treatment;
  • Participants who has contraindications to oral corticosteroids, such as serious gastric and duodenal ulcer, diabetes, glaucoma, etc;
  • Participants who have serious neurological or mental diseases, including dementia and seizures; 6.Participants who have oral corticosteroids history within 2 weeks, or who have recently taken a large amount of oral corticosteroids and are not suitable after the evaluation of the researcher;
  • Participants who have used corticosteroids therapy during the treatment of COVID-19 and olfactory function didn't recover;
  • Pregnant or lactating women;
  • persons without personal freedom and independent civil capacity;
  • Participants who have been enrolled in other intervention clinical trials;
  • Participants who with autoimmune diseases;
  • Participants who has any situation that may hinder the compliance of the protocol study or the safety during the study;
  • Other situations that the investigators think are not suitable for the trial.

研究组 & 干预措施

Glucocorticoid therapy with olfactory training

Experimental

olfactory training plus oral Glucocorticoid

干预措施: corticosteroids therapy (Drug)

Glucocorticoid therapy with olfactory training

Experimental

olfactory training plus oral Glucocorticoid

干预措施: Olfactory training (Other)

Olfactory training

Other

Olfactory training only

干预措施: Olfactory training (Other)

结局指标

主要结局

Olfactory function test result:the sum of the scores of odor threshold (T), odor discrimination (D), and odor identification (I) is TDI.

时间窗: 3 months

Olfactory tests combination of odor threshold (T), odor discrimination (D), and odor identification (I). The minimum values is zero, the maximum values of odor threshold (T), discrimination (D), and identification (I) is 16, the sum of the scores is TDI, which is between 0 to 48, the higher scores mean a better outcome.

次要结局

  • the Visual Analogue Scale(VAS)of olfactory function(3 months)
  • Odor threshold (T), Odor Discrimination (D), Odor Identification (I)(3 months)
  • Questionnaire of Olfactory Disorders(3 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验